HTA84 Cost-Utility Analysis of Talazoparib Versus Chemotherapy for Patients with Breast Cancer HER2- with Mutation in the BRCA1/2 Gene from the Brazilian Private Healthcare System
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.1513
https://www.valueinhealthjournal.com/article/S1098-3015(23)01613-3/fulltext
Title :
HTA84 Cost-Utility Analysis of Talazoparib Versus Chemotherapy for Patients with Breast Cancer HER2- with Mutation in the BRCA1/2 Gene from the Brazilian Private Healthcare System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01613-3&doi=10.1016/j.jval.2023.03.1513
First page :
Section Title :
Open access? :
No
Section Order :
10917